Cardiol Therapeutics Inc. (CRDL)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $1.17
- As of
Kresmion compiles this page from CRDL's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Cardiol Therapeutics Inc. (CRDL): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-23.
See the full CRDL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CRDL on one page. Preview it with sample data, then open it live with a free account.
Preview the CRDL dossierActive events for CRDL
- mediumEarnings above estimates
Q2-2026: Beat consensus by 53.3%, EPS $-0.05 vs $-0.1071 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 63% of CRDL (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +797% to CRDL (2026Q2)
- medium13F: new position
Point72 Asset Management, L.P. new position in CRDL
- high13F: large increase
RENAISSANCE TECHNOLOGIES LLC added +236% to CRDL (2026Q2)
FREE, NO ACCOUNT
Every event on CRDL, as it fires
You are seeing 5 of 10 events recorded on CRDL since 2026-05-26.
The five above landed across 2 days. The other 5 were recorded on 2 other days. 5 of the 10 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CRDL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 14161Y200 · 2026Q2 | $844K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 14161Y200 · 2026Q2 | $819K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 14161Y200 · 2026Q2 | $792K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 14161Y200 · 2026Q2 | $19K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CRDL
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
CRDL against its peers
CRDL's return on equity of -189.2% ranks in the 4th percentile of 13 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-03-31.
| Metric | CRDL | Peer median | Percentile | n |
|---|---|---|---|---|
| Gross margin | n/a | 46.6% | n/a | 16 |
| Operating margin | n/a | -9.1% | n/a | 17 |
| Net margin | n/a | -26.1% | n/a | 17 |
| Return on equity | -189.2% | -35.9% | 4 | 13 |
Peers (18): DERM, TSNDF, AKBA, BGM, ADCT, JUSH, GRUSF, GLAS, CRLBF, AAWH, ZYBT, CWBHF, ELTP, CPIX, CGC, TLPH, VRNO, NIKA. Left out: PHBI (period gap), OGI (period gap), ASRT.D (no annual filing), LFCR (no annual filing), INCR (period gap), CTOR (no annual filing), BORAY (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (CRDL: 40-F), reported in CAD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CRDL on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CRDL for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.